Akanda Past Earnings Performance
Past criteria checks 0/6
Akanda's earnings have been declining at an average annual rate of -58%, while the Pharmaceuticals industry saw earnings declining at 2.2% annually. Revenues have been growing at an average rate of 80.7% per year.
Key information
-58.0%
Earnings growth rate
-36.8%
EPS growth rate
| Pharmaceuticals Industry Growth | 6.0% |
| Revenue growth rate | 80.7% |
| Return on equity | n/a |
| Net Margin | -1,494.2% |
| Last Earnings Update | 31 Dec 2023 |
Revenue & Expenses BreakdownBeta
How Akanda makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 2 | -32 | 6 | 0 |
| 30 Sep 23 | 3 | -24 | 11 | 0 |
| 30 Jun 23 | 4 | -15 | 15 | 0 |
| 31 Mar 23 | 3 | -12 | 17 | 0 |
| 31 Dec 22 | 3 | -8 | 20 | 0 |
| 30 Jun 22 | 0 | -7 | 15 | 0 |
| 31 Mar 22 | 0 | -7 | 10 | 0 |
| 31 Dec 21 | 0 | -2 | 3 | 0 |
| 31 Dec 20 | 0 | -2 | 1 | 0 |
Quality Earnings: AKAN is currently unprofitable.
Growing Profit Margin: AKAN is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: AKAN is unprofitable, and losses have increased over the past 5 years at a rate of 58% per year.
Accelerating Growth: Unable to compare AKAN's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: AKAN is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (3.7%).
Return on Equity
High ROE: AKAN's liabilities exceed its assets, so it is difficult to calculate its Return on Equity.